McKesson Corporation, a prominent entity in the healthcare distribution sector, experienced significant executive-level transaction activity and reported complex financial results for its fourth quarter of fiscal year 2026. The period was marked by a substantial divestment by the company’s leadership, alongside financial metrics that revealed both strengths and challenges in its operational performance.
On July 7, 2026, Brian S. Tyler, the Chief Executive Officer of McKesson Corp., sold 8,463 shares of the company’s common stock. The transaction was executed at a price of $793.56 per share, resulting in a total value of approximately $6,715,898. This sale was conducted in compliance with Rule 10b5-1(c), pursuant to a pre-arranged trading plan that Tyler adopted on December 15, 2025. Following the execution of this sale, Mr. Tyler’s direct holding in McKesson common stock stands at 5,919 shares. Additionally, he maintains an indirect interest of 215.9211 shares through the McKesson Corporation 401(k) Retirement Savings Plan.
The stock performance surrounding this transaction indicates a positive trajectory for investors over the recent past. The stock has climbed to $818.66, delivering an 11.95% return over the past year. At the time of reporting, the share price was recorded at $818.66, reflecting a daily increase of 0.00% with a volume of 0.00% after hours, closing at 15:59:59 USD. The asset shows a 1D change of +11.33 (+1.40%).
Financial analysis suggests that McKesson may currently be trading at undervalued levels relative to its fundamental health. The company has earned a "GREAT" financial health score of 3.19 out of 5. Furthermore, McKesson has demonstrated consistent capital return to shareholders, having raised its dividend for 18 consecutive years. Dividend growth reached 15.49% over the last twelve months, highlighting a strong commitment to shareholder value amidst operational shifts.
McKesson’s fourth-quarter earnings for fiscal year 2026 presented a mixed financial performance profile. The company successfully surpassed earnings per share (EPS) expectations, reporting an EPS of $11.69 against a forecast of $11.57. This indicates effective cost management or margin expansion in its core operations. However, the top-line revenue fell short of market expectations. McKesson’s revenue came in at $92.3 billion, against an anticipated figure of $101.23 billion. This discrepancy between earnings beat and revenue miss suggests potential headwinds in volume or pricing within its distribution channels.
In a significant strategic development, McKesson completed a $1.25 billion investment from Apollo-managed funds into its Medical-Surgical Solutions business. This transaction involves Apollo Funds acquiring a 13% interest in the unit, which values the business at approximately $13 billion. This move signals a potential shift in capital structure or a strategic partnership aimed at bolstering the medical-surgical segment.
Broader industry dynamics also influenced the reporting period. Bank of America reported that oral Wegovy reached 33% of total prescriptions by May. The oral version of Wegovy, introduced in January, has quickly gained traction, stabilizing in the low-30% range of total prescriptions. This rapid adoption highlights significant movements within the pharmaceutical sector, potentially impacting demand patterns for healthcare distributors like McKesson.